• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Aeterna Zentaris Inc. (Amendment)

    2/11/22 6:41:14 AM ET
    $AEZS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEZS alert in real time by email
    SC 13G/A 1 ea155256-13ga2intra_aeterna.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

    Aeterna Zentaris Inc.

     

    (Name of Issuer)

     

    Common shares, no par value per share

     

    (Title of Class of Securities)

     

    007975402

     

    (CUSIP Number)

     

    December 31, 2021

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 6

     

     

    CUSIP No. 007975402  

     

    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization United States of America
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power 0
         
    6. Shared Voting Power 289,856
         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power 289,856
           
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 289,856 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 0.2% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      IN; HC  

     

    Page 2 of 6

     

     

    CUSIP No. 007975402  

     

    1. Names of Reporting Persons.
       
      Daniel B. Asher
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization United States of America
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power 0
         
    6. Shared Voting Power 289,856
         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power 289,856
           
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 289,856 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 0.2% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      IN; HC  

     

    Page 3 of 6

     

     

    CUSIP No. 007975402

     

    1. Names of Reporting Persons.
       
      Intracoastal Capital LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization Delaware
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power 0
         
    6. Shared Voting Power 289,856
         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power 289,856
           
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 289,856 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 0.2% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      OO  

     

    Page 4 of 6

     

     

    This Amendment No. 2 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on July 10, 2020, as amended by Amendment No. 1 thereto filed by the Reporting Persons with the SEC on January 29, 2021 (the “Schedule 13G”).

     

    Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

     

    Item 4. Ownership.

     

    (a) and (b):

     

    As of the close of business on December 31, 2021, each of the Reporting Persons may have been deemed to have beneficial ownership of 289,856 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (the “Intracoastal Warrant”), and all such shares of Common Stock represented beneficial ownership of approximately 0.2% of the Common Stock, based on (1) 121,397,007 shares of Common Stock outstanding as of November 4, 2021 as reported by the Issuer, plus (2) 289,856 shares of Common Stock issuable upon exercise of the Intracoastal Warrant.

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote: 0.

     

    (ii) Shared power to vote or to direct the vote: 289,856.

     

    (iii) Sole power to dispose or to direct the disposition of 0.

     

    (iv) Shared power to dispose or to direct the disposition of 289,856.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 5 of 6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 11, 2022

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
         
      /s/ Daniel B. Asher
      Daniel B. Asher
         
      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

    Page 6 of 6

     

     

    Get the next $AEZS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AEZS

    DatePrice TargetRatingAnalyst
    10/25/2021$2.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AEZS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

      TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ:AEZS) (TSX:AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announces that the Company's name has been changed from "Aeterna Zentaris Inc." to "COSCIENS Biopharma Inc.", effective as of August 6, 2024 (the "Name Change"). In addition, the Company announces that, effective as of August 9, 2024, the Company's common shares (the "Common Shares") will begin trading on the Toronto Stock

      8/6/24 6:00:00 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

      TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the "AGSM") held today. Results of the AGSM The results of the vote in respect of the election of directors of the Company are set out below: Name of NomineeVotes For% ForVotes Against% AgainstRon

      7/16/24 4:05:00 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products

    $AEZS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Aeterna Zentaris Inc.

      SC 13G - Aeterna Zentaris Inc. (0001113423) (Subject)

      6/6/24 1:46:51 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aeterna Zentaris Inc. (Amendment)

      SC 13G/A - Aeterna Zentaris Inc. (0001113423) (Subject)

      2/11/22 6:41:14 AM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Aeterna Zentaris Inc. (0001113423) (Subject)

      2/16/21 2:50:58 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEZS
    Leadership Updates

    Live Leadership Updates

    See more
    • Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

      TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the "AGSM") held today. Results of the AGSM The results of the vote in respect of the election of directors of the Company are set out below: Name of NomineeVotes For% ForVotes Against% AgainstRon

      7/16/24 4:05:00 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer

      – Well-established finance professional with over 20 years of experience gained in pharmaceutical, biopharma and professional services sectors TORONTO, ONTARIO, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced the appointment of Giuliano La Fratta as Senior Vice President, Chief Financial Officer. Effective January 24th, 2022, Mr. La Fratta will be responsible for the finance-related leadership functions, succeeding Ms. Leslie Auld, the Company's current Senior Vice President,

      12/23/21 4:05:00 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEZS
    SEC Filings

    See more
    • SEC Form 6-K filed by Aeterna Zentaris Inc.

      6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

      8/13/24 8:05:36 AM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Aeterna Zentaris Inc.

      6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

      8/13/24 8:05:17 AM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Aeterna Zentaris Inc.

      6-K - Aeterna Zentaris Inc. (0001113423) (Filer)

      8/6/24 6:22:58 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEZS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on AEterna Zentaris with a new price target

      HC Wainwright & Co. initiated coverage of AEterna Zentaris with a rating of Buy and set a new price target of $2.00

      10/25/21 6:23:09 AM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care